61 results about "Dosage adjustment" patented technology

A generic treatment protocol is disclosed for therapeutically treating a patient via an implantable treatment device. Treatment steps can be defined to start and end at absolute times, or can be programmed via telemetry to start a certain amount of time after termination of a previously executed treatment step. Treatment steps have a treatment rate or dose attribute and a duration attribute. Treatment steps may optionally enable patient-activated bolus overlays. Patient-activated rate or dosage adjustments can also optionally be enabled. Repeated-execution treatment-step groups are also provided. Such treatment-step groups can have start and end times, a group duration, and a group total dose, each defined in a manner similar to that for a treatment step. Treatment-step groups include a repetition count, which could be set to a value that causes the group to repeat forever. Single execution treatment steps can, accordingly, be programmed to execute before and/or after a repeated-execution treatment-step group.

The invention provides an individual drug dosage adjustment method and device. The method comprises steps as follows: the individual feature value of a pharmacokinetic parameter of a designated drug for a patient is determined according to individual information and a group pharmacokinetic model of the designated drug; a time-variable prediction equation of the drug concentration level of the designated drug for the patient is determined according to the individual feature value of the pharmacokinetic parameter of the designated drug for the patient as well as a preset medication plan of the drug; individual dosage adjustment of the designated drug is performed on the patient on the basis of the prediction equation. The concentration of the drug in every patient corresponding to a preset medication plan is accurately predicted according to the individual information of the patient, accordingly, the preset medication plan is adjusted according to a prediction result, and risks caused by adjustment afterwards are avoided.

The clinical artificial trial and error method repetitively adjusts the dose constraint mode to optimize the plan because of the multi-objective performance of plan optimization and the unknown performance of dose constraint, which has the problems of low plan efficiency and quality uncertainty. The invention discloses an intensity modulated radiation therapy multi-objective optimization method based on voxel weight factor. The thinking mode in design of the plan designer is simulated and the constraint is automatically adjusted so as to guarantee the plan quality. According to the method, theconstraints are sorted and classified according to the clinical degree of importance for the area of interest dose constraints to form a constraint priority list, and then the dose constraints are adjusted according to the list. When the obtained solution does not meet the current constraint, the violation items are relaxed in turn according to the ascending order of priority; and when the obtained solution meets the current constraint, all the items are tightened (the violation dose constraints are tightened firstly) in turn according to the descending order of priority. The method is used for the cervical cancer patient and the result shows that the workload of the plan designer can be reduced and the plan quality can be improved.

The invention provides a method and a kit for genotype detection of CYP3a5*3 sites and relates to the field of molecular biology and medicine. Specific primers, probes and magnetic beads written intorelated report probes are designed for gene SNP sites related to risk of adverse reactions associated with dosage of tacrolimus and cyclosporine, and types of the SNP sites can be subjected to typingdetection. By means of the detection kit, the type of CYP3A5*3(G >A) in human whole blood samples can be detected sensitively and rapidly, reliable experimental evidence for application dosage adjustment of tacrolimus and cyclosporine can be provided for patients, adverse reactions are reduced, and clinical treatment is guided.

The invention provides a pneumatic needleless injector. The pneumatic needleless injector comprises a dosage adjustment assembly, a shell assembly, a piston assembly, a medicine bottle assembly, a control valve assembly and a needle cylinder assembly, wherein the needle cylinder assembly is positioned at one end of an inner shell, and is fixedly connected with the inner shell through a tightening nut; a plunger piston in the piston assembly is positioned inside a needle cylinder, the small end of a piston is positioned in a piston rod cavity of the inner shell, the large end of the piston is positioned in a piston cavity of the inner shell, and a dosage adjustment tube in the dosage adjustment assembly is positioned inside the piston cavity and is adjacent to the large end of the piston. An end cover in the dosage adjustment assembly is fixedly connected with the inner shell through threads; the dosage adjustment tube is connected with the end cover through threads, so that the effect of adjusting the dosage is achieved. A valve tube in the control valve assembly is positioned in a valve cavity of the inner shell, and operates by coordinating with a control valve, and thus the effect of controlling the movement of the piston is achieved. The medicine bottle assembly is fixedly connected with the shell assembly through screws, and one end of an infusion tube in the medicine bottle assembly is inserted on a water inlet valve cover, so that liquid medicine is conveyed into the needle cylinder.

The invention relates to a large numerical control floor type boring and milling machine ram deflection compensating device, which belongs to the field of mechanical equipment, and comprises a guide rail (3) arranged on a spindle box (2), a pressing plate (9) arranged on a ram (1), and an idler wheel (4) arranged on a connecting seat (5) and matched with the guide rail (3) in a rolling way. One end of a screwpair (12) is arranged on the pressing plate (9), the other end of the screwpair (12) is arranged on a slide block (8), and the connecting seat (5) is connected with the slide block (8) into a whole through a screw (6) and a spring (7). When the ram (1) is stretched out and drawn back, the pressing plate (9) and the slide block (8) drive the idler wheel (4) to move along the guide rail(3). The device has the characteristics of simplicity and convenience in installing and debugging, compensation dosage adjustment in time, and the like, so that the device is economical and practical, and has low investment cost and high promotional value.

The invention relates to an appliance for performing anaesthesia or analgosedation, comprising a dosing device (5) for the intravenous administration of an adjustable dose of at least one anaesthetic to a patient (1), a measuring device (2) for determining the concentration of the at least one anaesthetic in the exhaled air of the patient (1), means (4) for determining the effect of the at least one anaesthetic on the patient (1), preferably in the form of a depth of anaesthesia or depth of analgosedation, and a data processing device (7), which communicates via interfaces with the dosing device (5), the measuring device (2) and the means (4) for determining the effect and which, on the basis of the determined values of the parameters dosage, concentration and effect of the at least one anaesthetic, establishes a pharmacological model individualized to the patient (1) and, using the individualized pharmacological model that is established, calculates an individual dosage, optimized to the patient (1), of the at least one anaesthetic.

The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.

The invention discloses a medicine applying device for dermatology department. The device comprises a telescopic handle, a medicine guide pipe, a bent main body handle, an angle adjustment device, a rotation motor, a massage head, a medicine dosage adjustment device, a battery, a medicine feeding hole and a switch, wherein the medicine feeding hole is formed in one end of the telescopic handle; the medicine feeding hole is connected to the medicine guide pipe; the other end of the medicine guide pipe is connected to the massage head; the medicine dosage adjustment device is disposed on the telescopic handle; the battery is located inside the telescopic handle; the battery is connected to the rotary motor by a wire; and the telescopic handle, the bent main body handle, the angle adjustment device, the rotation motor and the massage head are connected in succession; and a medicine outlet hole is formed in the message head. The device disclosed by the invention is safe and convenient; working efficiency of nursing workers is increased; and the device is applicable to promotion and application.

A medical injection device, comprising: a housing having a first end cover and a second end cover provided at two ends thereof, respectively; a dial threaded rod, which is in threaded connected to the first end cover; and, a piston rod, which is used for expelling a dose, an upper end of the piston rod being connected to the dial threaded rod through a driving mechanism while a lower end thereof is in threaded connected to the second end cover. It further comprises a dosage adjustment mechanism, which is arranged between the dial threaded rod and the housing and used for driving the dial threaded rod to move in an axial direction of the housing.

Disclosed are methods and kits for pharmacokinetic profiling employing point-of-care or point of service self-sampling and allowing for dosage adjustments based on the pharmacokinetic profiles.

The invention relates to the technical field of medical technologies, in particular to an atorvastatin calcium tablet and a preparation method and application thereof. The atorvastatin calcium tablet comprises a tablet core and a coating wrapping the tablet core, and the tablet core is prepared from, by weight, 10-60 parts of atorvastatin calcium; 15-30 parts of a protective agent; 80-120 parts of a filling agent; 4-8 parts of a disintegrating agent; 0.3-1 part of a lubricant; the protective agent is prepared from anhydrous calcium hydrogen phosphate and hydroxyapatite subjected to modification treatment. The atorvastatin calcium tablet disclosed by the invention has the advantages of good stability and high dissolution rate. The preparation method of the atorvastatin calcium tablet comprises the steps of pretreatment, material weighing, primary mixing, total mixing, tabletting and coating, and the tablet prepared through the preparation method is high in dissolution rate and stable in drug effect. The atorvastatin calcium tablet can be applied to capsules, and has the advantages of convenience in dosage adjustment and high practicability in clinical application.

A method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. A method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. A method of defining therapeutic doses of a psychedelic in clinical trials. A method of monitoring individuals for depression after treatment with LSD.

The invention discloses a dosage adjustment device of a pipettor. The dosage adjustment device of the pipettor comprises a round tube part provided with a tooth punching end, double-layer gears and a digit wheel, wherein the tooth punching end of the round tube part is meshed with a small tooth layer of the double-layer gears, a big tooth layer of the double-layer gears is meshed with the digit wheel, the inside of the round tube part drives a sliding rod to slide, and anti-skid threads are arranged at the other end, opposite to the tooth punching part, of the outside of the round tube part and are used for rotation of the outside to adjust a dosage. Because a plurality of compact gears are meshed, on the premise that accurate dosage adjustment is ensured, strength for rotating adjustment is greatly reduced. Great strength is not needed, the dosage can be adjusted easily and accurately, the whole adjustment process is smooth in motion, and the dosage adjustment device of the pipettor is suitable for routine work carried out every day.

The invention relates to a medical apparatus, in particular to an injection tool and discloses a continuously-adjustable pneumatic needle-free injection apparatus. The injection apparatus comprises anampoule needle tubing, an ampoule needle tubing hoop, an ampoule barrel, an ampoule push rod, a shell, a piston handle, a piston rod, a spring, an air cylinder, a handle, an air pump, a two-positionthree-way valve and a switch. The injection apparatus is characterized in that an air inlet hole of the two-position three-way valve in the handle is communicated with the air pump through an air tubeand connected with the air cylinder through an inflation hole. The rear portion of the ampoule needle tubing mounted at the front end of the shell is provided with an external thread, matched with aninternal thread of the ampoule barrel, of the ampoule needle tubing hoop. The spring externally sleeves the piston rod mounted in the air cylinder and is in slide fit with the piston rod. The continuously-adjustable pneumatic needle-free injection apparatus is simple in structure, convenient to operate and available for continuous operation and injection dosage adjustment.

Provided is an oral pharmaceutical composition characterized by containing a medicinal ingredient (A), a hydrophobic liquid (B), a water-soluble macromolecular substance (C), and an excipient (D), but not containing a surfactant, wherein: the medicinal ingredient (A) is included in the hydrophobic liquid (B); and the hydrophobic liquid (B) is dispersed in a composition including the water-soluble macromolecular substance (C) and the excipient (D). The oral pharmaceutical composition: allows easy dose-adjustment; has excellent dosability and safety; is biologically equivalent to a standard formulation having established profiles regarding efficacy, safety, etc.; and can be easily produced.

The invention discloses an insulin dosage form selection and dosage adjustment method and system, and the method comprises the steps: giving an insulin scheme suitable for a patient based on a diabetes guide/expert consensus through and a machine learning model, wherein the insulin scheme comprises the time of taking insulin and a corresponding insulin dosage form; collecting patient medical records of type 2 diabetes mellitus, wherein each medical record includes examination and inspection during hospitalization of the patient, one-statement five-history, medical advice and basic attribute data of the patient, and establishing characteristic fields according to the medical records; substituting the characteristic fields into an Xgboost model to carry out machine learning training so as totrain characteristic variables in the model; establishing an insulin initial total dose model, and substituting the characteristic fields of the medical records of the patient into the Xgboost modelfor machine learning training to obtain an insulin initial total dose, wherein insulin is divided into three types: basic insulin, premixed insulin and dinner insulin, and is divided into seven typesaccording to different injection time; establishing insulin dose adjustment model.

The invention discloses an oxygen atomizing device facilitating administration dosage adjustment. The oxygen atomizing device comprises an oxygen atomizing device body, a connecting pipe is clamped onthe front surface of the oxygen atomizing device body, an operation head is fixedly mounted at one end of the connecting pipe, a casing is arranged in the middle position of the connecting pipe, connecting ports are formed in two ends of the casing, a winding shaft is rotationally connected in the middle position of the inside of the casing through a bearing, and baffle rings are fixed at two ends of the winding shaft. By design of the casing in the middle position of the connecting pipe and the winding shaft in the casing, the condition that the length of the connecting pipe is inconvenientto adjust when the oxygen atomizing device is not used, when use inconvenience is caused due to too long or too short connecting pipe, a user can hold a crank to drive the winding shaft to roll in thecasing through the bearing to wind the connecting pipe around the outer surface of the winding shaft to adjust the length of the connecting pipe, so that the connecting pipe is at certain length andthe operation head is used stably.

A packaging container for a drug having a recording medium and/or an identification mark for recording and updating one or more arbitrary information(s) selected from the group consisting of the information: an active ingredient of a drug, usage of a drug, drug dose, date of manufacture of a drug, expiration date of a drug, drug shipping date of a drug, traceability of drug delivery route from manufacturing to usage of a drug, and storage conditions (e.g., temperature, light (dark/light), humidity, etc.) including storage temperature and changes thereof, information including the administration date of a drug and a breakdown of the administration, amount of drug presented in drug-enclosing portion.